White Papers

White Paper Download

Sponsors and clinical research organizations (CROs) are being very cautious in their utilization of adaptive clinical trial designs. And well they should be. While under the right circumstances, clinical trials can enhance the ethical treatment of patients, enable better decisions faster and help minimize the cost of clinical development, it is important to keep in mind that adaptive trials will not always be appropriate. This paper from Elsevier Business Intelligence discusses how adaptive clinical trials can provide a better way to explore and demonstrate the efficacy and safety of investigational products, while also emphasizing the point that a trial that forgoes validity for novelty is not a good trial.

Have a SAS profile? Log in to pre-fill the form.

*  First Name
*  Last Name
*  E-mail Address
* Organization/Company
* Industry
* Job Title
*  Country
(Required for Canada and U.S.)
* Business Phone
Yes, I would like to opt-in to receive occasional emails from SAS and its affiliates
about SAS events, free white papers, special offers on training and publications, etc.
All personal information will be handled in accordance with the SAS Privacy Statement.

( * indicates required field )